1
|
Soumaré D, Ouattara K, Kanouté T, Gakou B, Baya B, Guindo I, Sidibe F, Sanogo FB, Bamba S, Koné D, Kamian Y, Oumarou Y, Dakouo AP, Coulibaly L, Koné S, Djigandé G, Coulibaly A, Toloba Y. [Community acute bacterial pneumonitis of the subject age in pulmonology at the Point-g hospital and university center, Bamako-Mali]. Mali Med 2022; 37:54-57. [PMID: 38514959] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 03/23/2024]
Abstract
INTRODUCTION Community-acquired acute bacterial pneumonia (ABP) is an acute, non-suppurative, non-tuberculosis lower respiratory infection of the lung parenchyma acquired within the community. They have an atypical clinical presentation and a poor prognosis in the elderly. MATERIALS AND METHODS This was a prospective cross-sectional study conducted in the Pneumology department of the University Hospital Center (CHU) of Point-G, from October 30, 2018 to September 30, 2019. The objective was to determine the clinical, etiological, therapeutic and progression of BAP in the elderly. Were included any age ≥ 65 years, presenting clinical and radiological signs of a PAB. RESULTS During the study period, 85 patients met the inclusion criteria out of 178 hospitalized. The sex ratio was 3/1. About 2/3 were smokers and 11% were HIV positive. Fever was not constant recorded in 51.76% of cases. Respiratory signs were dominated by cough (96.47%), dyspnea (94.11%) and extra respiratory by impaired consciousness. Klebsiella pneumoniae was the most found germ. The most commonly used antibiotic was amoxicillin-clavulanic acid. The average length of hospitalization was 9 days. Mortality was 19%. CONCLUSION The PAB in the elderly is of a frustrating clinical symptomatology. It is serious with excess mortality.
Collapse
Affiliation(s)
- D Soumaré
- Service de Pneumo-phtisiologie CHU Point-G
| | - K Ouattara
- Service de Pneumo-phtisiologie CHU Point-G
| | - T Kanouté
- Service de Pneumo-phtisiologie CHU Point-G
| | - B Gakou
- Centre de Santé Communautaire de Missira (Commune II du district de Bamako-Mali)
| | - B Baya
- Service de Pneumo-phtisiologie CHU Point-G
| | - I Guindo
- Service de Pneumo-phtisiologie CHU Point-G
| | - F Sidibe
- Service de Pneumo-phtisiologie CHU Point-G
| | - F B Sanogo
- Service de Pneumo-phtisiologie CHU Point-G
| | - S Bamba
- Service de Pneumo-phtisiologie CHU Point-G
| | - D Koné
- Service de Pneumo-phtisiologie CHU Point-G
| | - Y Kamian
- Service de Pneumo-phtisiologie CHU Point-G
| | - Y Oumarou
- Service de Pneumo-phtisiologie CHU Point-G
| | - A P Dakouo
- Service de Pneumo-phtisiologie CHU Point-G
| | | | - S Koné
- Service de Pneumo-phtisiologie CHU Point-G
| | - G Djigandé
- Service de Pneumo-phtisiologie CHU Point-G
| | | | - Y Toloba
- Service de Pneumo-phtisiologie CHU Point-G
| |
Collapse
|
2
|
Tolofoudie M, Somboro A, Diarra B, Sarro YS, Drame HB, Togo ACG, Sanogo M, Dembele A, Togun T, Nkereuwem E, Baya B, Konate B, Egere U, Traore M, Maiga M, Saliba-Shaw K, Kampmann B, Diallo S, Doumbia S, Sylla M. Isoniazid preventive therapy in child household contacts of adults with active TB in Bamako, Mali. Public Health Action 2021; 11:191-195. [PMID: 34956847 PMCID: PMC8680184 DOI: 10.5588/pha.21.0061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2021] [Accepted: 08/16/2021] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND AND OBJECTIVE Isoniazid preventive therapy (IPT) is known to reduce the risk of developing active TB in about 59% in children aged ⩽15 years. We assessed adherence, completion and adverse events among children who were household contacts of a newly diagnosed adult with smear-positive TB in Bamako, Mali. METHODS Children aged <15 years living in the same house with an adult smear-positive index case were enrolled in the study in the Bamako Region after consent was obtained from the parent or legal guardian. Adherence was assessed based on the number of tablets consumed during 6 months. RESULTS A total of 260 children aged <15 years were identified as household contacts of 207 adult patients with smear-positive TB during the study period. Among all child contacts, 130/260 (50.0%) were aged 0-4 years and were eligible for IPT; 128/130 (98.5%) were started on IPT and 83/128 (64.8%) completed with good adherence at the end of the 6 months, and without any significant adverse events. CONCLUSION We successfully implemented IPT with good acceptance, but low completion rate. The Mali National TB Program and partners should expand this strategy to reach more children in Bamako and the whole country and create greater awareness in the population.
Collapse
Affiliation(s)
- M Tolofoudie
- University Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - A Somboro
- University Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - B Diarra
- University Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Y S Sarro
- University Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - H B Drame
- University Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - A C G Togo
- University Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - M Sanogo
- University Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - A Dembele
- Department of Paediatrics, University Teaching Hospital of Gabriel Toure, Bamako, Mali
| | - T Togun
- Vaccines and Immunity Theme, Medical Research Council Unit-The Gambia, Banjul, The Gambia
| | - E Nkereuwem
- Vaccines and Immunity Theme, Medical Research Council Unit-The Gambia, Banjul, The Gambia
| | - B Baya
- University Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - B Konate
- National Tuberculosis Control Program, Ministry of Health and Public Hygiene, Bamako, Mali
| | - U Egere
- Vaccines and Immunity Theme, Medical Research Council Unit-The Gambia, Banjul, The Gambia
| | - M Traore
- Health Referral Center Five, Ministry of Health and Social Development, Bamako, Mali
| | - M Maiga
- Center for Innovation in Global Health Technology, Northwestern University, Chicago, IL, USA
| | - K Saliba-Shaw
- Collaborative Clinical Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases/National Institutes of Health, Bethesda, MD, USA
| | - B Kampmann
- Vaccines and Immunity Theme, Medical Research Council Unit-The Gambia, Banjul, The Gambia
| | - S Diallo
- University Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - S Doumbia
- University Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - M Sylla
- Department of Paediatrics, University Teaching Hospital of Gabriel Toure, Bamako, Mali
| |
Collapse
|
3
|
Diarra B, Decroo T, Somboro A, Coulibaly G, Tolofoudie M, Kone M, Degoga B, Diallo F, Togo ACG, Sanogo M, Sarro YS, Cisse AB, Kodio O, Baya B, Kone A, Maiga M, Dao S, Maiga II, Murphy RL, Siddiqui S, Toloba Y, Konate B, Diakite M, Doumbia S, Van Deun A, Rigouts L, Diallo S, de Jong BC. Fluorescein diacetate and rapid molecular testing for the early identification of rifampicin resistance in Mali. Int J Tuberc Lung Dis 2021; 24:763-769. [PMID: 32912379 DOI: 10.5588/ijtld.19.0698] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND: Non-conversion on auramine smear microscopy indicates a lack of treatment response, possibly associated with initial rifampicin-resistant tuberculosis (RR-TB). However, dead bacteria still stain positive and may be detected. Fluorescein diacetate smear microscopy (FDA) shows live mycobacteria only. Therefore, we studied the potential of 2-month (2M) FDA for the identification of initial RR-TB.METHODS: Between 2015 and 2018, we enrolled new smear-positive pulmonary TB patients from five local centres in Bamako, Mali. After baseline screening, sputum samples were collected at 1M, 2M, 5M and 18M. We used rpoB sequencing to identify initial RR-TB.RESULTS: Of 1359 patients enrolled, 1019 (75%) had rpoB sequencing results. Twenty-six (2.6%, 95%CI: 1.7-3.7) had mutations conferring rifampicin resistance. Most frequent rpoB mutations were located at the codons Asp435Val (42.4%) and Ser450Leu (34.7%). Among patients with initial RR-TB, 72.2% were FDA-negative at 2M (P = 0.2). The positive and negative predictive value of 5M FDA for culture-based failure was respectively 20.0% and 94.7%.CONCLUSION: FDA did not identify the majority of patients with initial RR-TB or culture-based failure. As the full spectrum of mutations identified on sequencing was identified using Xpert, our data support its rapid universal implementation in Mali.
Collapse
Affiliation(s)
- B Diarra
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali, Unit of Mycobacteriology, Institute of Tropical Medicine Antwerp, Antwerp
| | - T Decroo
- Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Antwerp, Research Foundation Flanders, Brussels, Belgium
| | - A Somboro
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - G Coulibaly
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - M Tolofoudie
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - M Kone
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - B Degoga
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - F Diallo
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - A C G Togo
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - M Sanogo
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Y S Sarro
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - A B Cisse
- Laboratoire National de Référence des Mycobactéries, Institut National de Recherche en Santé publique, Bamako, Mali
| | - O Kodio
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - B Baya
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - A Kone
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - M Maiga
- Global Health, Northwestern University, Chicago, IL, USA
| | - S Dao
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - I I Maiga
- Laboratoire d´analyses Médicales et Hygiène Hospitalière du Centre Hospitalier Universitaire du Point-G, Bamako, Mali
| | - R L Murphy
- Laboratoire National de Référence des Mycobactéries, Institut National de Recherche en Santé publique, Bamako, Mali
| | - S Siddiqui
- Collaborative Clinical Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
| | - Y Toloba
- Service de Pneumo-phtisiologie du Centre Hospitalier Universitaire du Point-G, Bamako
| | - B Konate
- Programme National de Lutte contre la Tuberculose (PNLT), Ministère de la santé et des Affaires Sociales, Bamako, Mali
| | - M Diakite
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - S Doumbia
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | | | - L Rigouts
- Unit of Mycobacteriology, Institute of Tropical Medicine Antwerp, Antwerp, Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
| | - S Diallo
- University Clinical Research Centre, SEREFO Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - B C de Jong
- Unit of Mycobacteriology, Institute of Tropical Medicine Antwerp, Antwerp
| |
Collapse
|
4
|
Coulibaly N, Kone B, Sanogo M, G Togo AC, Diarra B, Sarro YS, Cisse AB, Kodio O, Coulibaly G, Kone M, Baya B, Maiga M, Dabitao D, Belson M, Dao S, Diallo S, Diakite M, Babana AH, Doumbia S. Performance of Mali's biosafety level 3 laboratory in the external quality assessment in preparedness of laboratory accreditation and support to clinical trials. Int J Mycobacteriol 2021; 9:29-33. [PMID: 32474485 PMCID: PMC8075184 DOI: 10.4103/ijmy.ijmy_5_20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
Background: The external quality assessment (EQA) or external quality control is an evaluation conducted by a certified external organization to inquire about the quality of the results provided by a laboratory. The primary role of EQA is to verify the accuracy of laboratory results. This is essential in research because research data should be published in international peer-reviewed journals, and laboratory results must be repeatable. In 2007, the University Clinical Research Center (UCRC’s) biosafety level 3 (BSL-3) laboratory joined the EQA program with the College of American Pathologists in acid-fast staining and culture and identification of mycobacteria as per laboratory accreditation preparedness. Thus, after 11 years of participation, the goal of our study was to evaluate the performance of our laboratory during the different interlaboratory surveys. Methods: We conducted a descriptive retrospective study to evaluate the results of UCRC mycobacteriology laboratory from surveys conducted during 2007 and 2017. Results: Of the 22 evaluations, the laboratory had satisfactory (100% of concordance results) in 18 (81.8%) and good (80% of concordance results) in 4 (18.2%). Overall, the laboratory was above the commended/accepted limits of 75%. Conclusion: So far, UCRC’s BSL-3 performed well during the first 11 years of survey participation, and efforts should be deployed to maintain this high quality in the preparedness for laboratory accreditation and support to clinical trials.
Collapse
Affiliation(s)
- N Coulibaly
- University Clinical Research Center-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - B Kone
- University Clinical Research Center-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - M Sanogo
- University Clinical Research Center-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - A C G Togo
- University Clinical Research Center-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - B Diarra
- University Clinical Research Center-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Y S Sarro
- University Clinical Research Center-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - A B Cisse
- National Referral Laboratory of Mycobacteriology, National Institute of Public Health, INSP, Bamako, Mali
| | - O Kodio
- University Clinical Research Center-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - G Coulibaly
- University Clinical Research Center-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - M Kone
- University Clinical Research Center-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - B Baya
- University Clinical Research Center-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - M Maiga
- University Clinical Research Center-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali; Center for Global Health, Northwestern University, Chicago, IL, USA
| | - D Dabitao
- University Clinical Research Center-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - M Belson
- Collaborative Clinical Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
| | - S Dao
- University Clinical Research Center-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - S Diallo
- University Clinical Research Center-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - M Diakite
- University Clinical Research Center-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - A H Babana
- Microbiology and Biotechnology Research Laboratory, Faculty of Sciences and Techniques, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - S Doumbia
- University Clinical Research Center-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| |
Collapse
|
5
|
Diarra B, Tolofoudie M, Sarro YS, Togo ACG, Bane S, Nientao I, Cisse AB, Kone M, Somboro A, Degoga B, Diallo F, Coulibaly G, Kodio O, Sanogo M, Kone B, Diabate S, Baya B, Kone A, Dabitao D, Maiga M, Belson M, Dao S, Maiga II, Murphy RL, Siddiqui S, Toloba Y, Konate B, Doumbia S, de Jong BC, Diallo S. Diabetes Mellitus among new tuberculosis patients in Bamako, Mali. J Clin Tuberc Other Mycobact Dis 2019; 17:100128. [PMID: 31788570 PMCID: PMC6879999 DOI: 10.1016/j.jctube.2019.100128] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
Abstract
Introduction Diabetes Mellitus (DM) increases worldwide, mostly in low- and middle-income countries. In Mali, the prevalence in the adult population is estimated at 1.8%, but tuberculosis (TB) patients are not systematically screened. The goal of our study was to determine the prevalence of DM among newly diagnosed TB patients. Methods We conducted a cross sectional study and a pilot prospective cohort study in four health centers in Bamako. All patients underwent fasting capillary-blood glucose (FCBG) test at Day 0, and repeated after one-week of TB treatment. Venous FBG test was performed for discrepancies between the two FCBG results. Thereafter, FCBG was performed for pilot study at month-2 (M2) and M5 of TB treatment. Results Two hundred and one patients were enrolled in this study. Impaired fasting blood glucose was identified in 17 (8.5%), of whom 11 (5.5%) had DM (VFBG >7 mmol/L). Among patients with DM, seven (63.6%) had successful TB treatment outcome, versus 142 (74.7%) of those without DM (p = 0.64), and (OR: 1.69, 95%CI 0.47–6.02). Conclusion The prevalence of DM among TB patients in Bamako exceeds that of the general population and screening at TB diagnosis suffices to identify those with DM. Systematic screening of both diseases will allow better treatment.
Collapse
Affiliation(s)
- B Diarra
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali.,Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
| | - M Tolofoudie
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - Y S Sarro
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - A C G Togo
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - S Bane
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - I Nientao
- Service de Médecine et d'Endocrinologie de l'hôpital du Mali, Bamako, Mali
| | - A B Cisse
- Laboratoire National de Référence des Mycobactéries (LNR), Institut National de Recherche en Santé publique (INRSP), Bamako, Mali
| | - M Kone
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - A Somboro
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - B Degoga
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - F Diallo
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - G Coulibaly
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - O Kodio
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - M Sanogo
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - B Kone
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - S Diabate
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - B Baya
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - A Kone
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - D Dabitao
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - M Maiga
- Global Health, Northwestern University, Chicago, IL, United States
| | - M Belson
- Collaborative Clinical Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, United States
| | - S Dao
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - I I Maiga
- Laboratoire d'analyses Médicales et Hygiène Hospitalière du Centre Hospitalier Universitaire du Point-G, Bamako, Mali
| | - R L Murphy
- Global Health, Northwestern University, Chicago, IL, United States
| | - S Siddiqui
- Collaborative Clinical Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, United States
| | - Y Toloba
- Service de Pneumo-phtisiologie du Centre Hospitalier Universitaire du Point-G, Bamako, Mali
| | - B Konate
- Programme National de Lutte contre la Tuberculose (PNLT), Ministère de la santé et de l'hygiène publique, Bamako, Mali
| | - S Doumbia
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - B C de Jong
- Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
| | - S Diallo
- University Clinical Research Center (UCRC)-SEREFO-Laboratory, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| |
Collapse
|
6
|
Ouattara K, Soumare D, Baya B, Kanoute T, Guindo I, Bamba S, Kamian Y, Dakouo A, Sanogo F, Fofana A, Coulibaly L, Yossi O, Kone I, Berthe G, Sidibe F, Toloba Y. Sensibilisation acariens-arachide chez les enfants dans un pays d’Afrique sub-saharienne. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
7
|
Soumare D, Kanouté T, Ouattara K, Baya B, Guindo I, Sidibé F, Tall M, Sanogo F, Bamba S, Koné D, Kamian Y, Yossi O, Dakouo A, Coulibaly L, Berthé G, Toloba Y. Abcès du poumon : aspects épidémio-cliniques et évolutif au service de pneumo-phtisiologie du CHU du Point G. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.498] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
8
|
Kanoute T, Ouattara K, Soumare D, Baya B, Sidibe F, Guindo I, Yossi O, Kone D, Kamian Y, Dakouo A, Sanogo F, Bamba S, Coulibaly L, Berthe G, Toloba Y. Tuberculose et tabagisme : aspects cliniques et radiologiques. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
9
|
Kanoute T, Soumare D, Ouattara K, Baya B, Guindo I, Sidibe F, Kone S, Kone D, Kamian Y, Yossi O, Dakouo A, Coulibaly L, Bamba S, Sanogo F, Berthe G, Toloba Y. Aspects cliniques et étiologiques de la dilatation des bronches (DDB) à Bamako. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
10
|
Senghore M, Diarra B, Gehre F, Otu J, Worwui A, Muhammad A, Sanogo M, Baya B, Orsega S, Doumbia S, Diallo S, de Jong B, Pallen M, Antonio M. Evolution of virulent genotypes and an emerging threat of multidrug resistant tuberculosis in Bamako, Mali. Int J Infect Dis 2018. [DOI: 10.1016/j.ijid.2018.04.3573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
11
|
Toloba Y, Ouattara K, Soumaré D, Kanouté T, Berthé G, Baya B, Konaté B, Keita M, Diarra B, Cissé A, Camara FS, Diallo S. [Multidrug-resistant tuberculosis (MDR-TB) in a black African carceral area: Experience of Mali]. Rev Pneumol Clin 2018; 74:22-27. [PMID: 29246463 DOI: 10.1016/j.pneumo.2017.10.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/08/2017] [Revised: 08/04/2017] [Accepted: 10/30/2017] [Indexed: 06/07/2023]
Abstract
INTRODUCTION Prison constitutes a risk factor for the emergence of multi-drug resistance of tuberculosis (MDR-TB). The aim of this work was to study MDR-TB in a black African carceral center. MATERIAL AND METHODS Prospective study from January to December 2016 at the central house of arrest for men, Bamako. The study population was composed of tuberculous detainee. The suspicion of MDR-TB was done in any tuberculosis case remained positive in the second month of first-line treatment or in contact with an MDR-TB case. RESULT Among 1622 detainee, 21 cases of pulmonary tuberculosis were notified (1.29%), with an annual incidence of 13 cases/1000 detainee, they were 16 cases of SP-PTB (microscopy smear positive tuberculosis) and five cases of microscopy smear negative tuberculosis. The mean age was 28±7 years, extremes of 18 and 46 years. A negative association was found between the notion of smoking and occupation in the occurrence of tuberculosis (OR=0.036, [95% CI: 0.03-0.04], P=0.03. Among the 21 tuberculosis cases notified, one confirmed case of MDR-TB was detected (4.7%). In the first semester of 2016 cohort, we notified a cure rate of 87.5% (7/8 SP-PTB cases), and the confirmed MDR-TB case on treatment (21-month regimen), evolution enameled of pulmonary and hearing sequelae at seven months treatment. CONCLUSION It was the first case of MDR-TB detected in a prison in Mali. Late diagnosis, evolution is enameled of sequelae and side effects.
Collapse
Affiliation(s)
- Y Toloba
- Service de pneumologie, CHU du Point-G, E1631 Bamako, Mali.
| | - K Ouattara
- Service de pneumologie, CHU du Point-G, E1631 Bamako, Mali
| | - D Soumaré
- Service de pneumologie, CHU du Point-G, E1631 Bamako, Mali
| | - T Kanouté
- Service de pneumologie, CHU du Point-G, E1631 Bamako, Mali
| | - G Berthé
- Service de pneumologie, CHU du Point-G, E1631 Bamako, Mali
| | - B Baya
- Service de pneumologie, CHU du Point-G, E1631 Bamako, Mali
| | - B Konaté
- Programme national de lutte contre la tuberculose (PNLT-Mali), Mali
| | - M Keita
- Maison centrale d'arrêt de Bamako (MCA), Bamako, Mali
| | - B Diarra
- Centre de formation et de recherche (SEREFO), Mali
| | - A Cissé
- Institut national de recherche en santé publique (INRSP), Mali
| | - F S Camara
- Institut national de recherche en santé publique (INRSP), Mali
| | - S Diallo
- Service de pneumologie, CHU du Point-G, E1631 Bamako, Mali; Centre de formation et de recherche (SEREFO), Mali
| |
Collapse
|
12
|
Toloba Y, Soumaré D, Ouattara K, Kanouté T, Boré O, Dolo O, Baya B, Berthé G, Diallo S. [Respiratory diseases in black African carceral area]. Rev Mal Respir 2017; 34:729-733. [PMID: 28844810 DOI: 10.1016/j.rmr.2016.10.878] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2015] [Accepted: 10/26/2016] [Indexed: 11/24/2022]
Abstract
INTRODUCTION The measures for people in specific situations such as prisoners are part of the Millennium Development Goals (MDGs). The objective of this study was to assess respiratory pathologies in a black African carceral center. METHODS Retrospective study about the prevalence of respiratory pathologies in the arrest central house for men in Bamako (Mali), from May 2012 to April 2013. The admission records have served as data checking support on detainee's records. Statistical significance was investigated by the SAS 9.3 software with a threshold of 5%. RESULTS Of 2740 admissions, 207 concerned respiratory pathologies (7.5%). All men, were of mean age 30±13 years (range 19-71). The respiratory diseases found were: pneumonia (33.8%), chronic bronchitis (26.6%), acute respiratory infection (14%), asthma (13.5%) and tuberculosis (5.3%). A definite diagnosis was made in 42% of cases. A tobacco intoxication was found in all age groups (CI 95%, R-square=0.01), without significant difference between the occurrence of cough in smoking and non-smoking men. CONCLUSION According to their relative frequencies, the management of respiratory diseases requires collaboration between carceral health facilities and pneumological specialized services.
Collapse
Affiliation(s)
- Y Toloba
- Service de pneumologie, CHU de Point-G, Bamako, Mali.
| | - D Soumaré
- Service de pneumologie, CHU de Point-G, Bamako, Mali
| | - K Ouattara
- Service de pneumologie, CHU de Point-G, Bamako, Mali
| | - T Kanouté
- Service de pneumologie, CHU de Point-G, Bamako, Mali
| | - O Boré
- Maison centrale d'arrêt de Bamako, Bamako, Mali
| | - O Dolo
- Maison centrale d'arrêt de Bamako, Bamako, Mali
| | - B Baya
- Service de pneumologie, CHU de Point-G, Bamako, Mali
| | - G Berthé
- Service de pneumologie, CHU de Point-G, Bamako, Mali
| | - S Diallo
- Service de pneumologie, CHU de Point-G, Bamako, Mali
| |
Collapse
|
13
|
Kone B, Maiga M, Baya B, Sarro YDS, Coulibaly N, Kone A, Diarra B, Sanogo M, Togo ACG, Goita D, Dembele M, Polis MA, Warfield J, Belson M, Dao S, Orsega S, Murphy RL, Diallo S, Siddiqui S. Establishing Reference Ranges of Hematological Parameters from Malian Healthy Adults. J Blood Lymph 2017; 7:154. [PMID: 29423342 PMCID: PMC5800422 DOI: 10.4172/2165-7831.1000154] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
INTRODUCTION Measurement of immuno-hematological parameters has been historically helpful in the diagnosis and treatment monitoring of many infectious diseases and cancers. However, these parameters have not yet been established in many developing countries where patient care strongly relies on such low-cost tests. This study describes the immuno-hematological parameter ranges for Malian healthy adults. METHODS A cross sectional study was conducted from August 2004 to May 2013. We included 213 healthy volunteers (173 male and 40 female), aged between 18-59 years. Median, 2.5 and 97.5 percentile ranges for each immuno-hematological parameter are presented. RESULTS In our study population, the hematological parameters' ranges were mostly different to the universal established ranges. We found in our population a Median white blood cell (WBC) count of 5200 cells/μL [3237.5-11900], Red Blood Cell (RBC) count of 4.94 10^6 [3.56-6.17], hemoglobin (Hb) of 14.2 g/dL [12.2-17.38], platelet count (Plt) of 275 10^3/μL [145.4-614.4], lymphocytes 2050/μL [1200-3800], neutrophils 2200/μL [1040-6220]; monocytes 200/μL [100-660]; eosinophils 131/μL [0-1026]; CD4 902 cells/μL [444-1669] and CD8 485 cells/μL [0-1272]. We found significant gender differences in RBC, Hb level and MPV. However, RBC and Hb were higher in males median values compared to females (median values) (p<0.001), whereas the Mean platelet volume lower values (MPV) in males than females (P<0.047). The hemoglobin level for some West African countries (Mali, Burkina Faso, Togo, and Nigeria) ranged from 13.5 to 15.1 g/dL for males and 12 to 13 g/dL for females. However in East and Southern Africa, the values were anywhere from 14.1 to 16.1 for males and 11.2 to 14.4 for females. CONCLUSION Our data may help physicians to better define hematological abnormalities in patients. They may also be used to define new "normal hematological values" in Malian population or in the whole West African population.
Collapse
Affiliation(s)
- B Kone
- University of Sciences, Techniques and Technologies of Bamako, Mali
| | - M Maiga
- University of Sciences, Techniques and Technologies of Bamako, Mali
- Leidos Biomedical Research, Inc., in support to NIAID, Bethesda, Maryland, USA
- Northwestern University, Chicago, Illinois, USA
| | - B Baya
- University of Sciences, Techniques and Technologies of Bamako, Mali
| | - YDS Sarro
- University of Sciences, Techniques and Technologies of Bamako, Mali
| | - N Coulibaly
- University of Sciences, Techniques and Technologies of Bamako, Mali
| | - A Kone
- University of Sciences, Techniques and Technologies of Bamako, Mali
| | - B Diarra
- University of Sciences, Techniques and Technologies of Bamako, Mali
| | - M Sanogo
- University of Sciences, Techniques and Technologies of Bamako, Mali
| | - ACG Togo
- University of Sciences, Techniques and Technologies of Bamako, Mali
| | - D Goita
- University of Sciences, Techniques and Technologies of Bamako, Mali
| | - M Dembele
- University of Sciences, Techniques and Technologies of Bamako, Mali
| | - MA Polis
- National Institute of Allergic and Infectious Diseases (NIAID), Bethesda, Maryland, USA
| | - J Warfield
- Leidos Biomedical Research, Inc., in support to NIAID, Bethesda, Maryland, USA
| | - M Belson
- National Institute of Allergic and Infectious Diseases (NIAID), Bethesda, Maryland, USA
| | - S Dao
- University of Sciences, Techniques and Technologies of Bamako, Mali
| | - S Orsega
- National Institute of Allergic and Infectious Diseases (NIAID), Bethesda, Maryland, USA
| | - RL Murphy
- Northwestern University, Chicago, Illinois, USA
| | - S Diallo
- University of Sciences, Techniques and Technologies of Bamako, Mali
| | - S Siddiqui
- National Institute of Allergic and Infectious Diseases (NIAID), Bethesda, Maryland, USA
| |
Collapse
|
14
|
Sanogo M, Kone B, Diarra B, Maiga M, Baya B, Somboro AM, Sarro YS, Togo ACG, Dembele BPP, Goita D, Kone A, M'Baye O, Coulibaly N, Diabate S, Traore B, Diallo MH, Coulibaly YI, Saleeb P, Belson M, Orsega S, Siddiqui S, Polis MA, Dao S, Murphy RL, Diallo S. Performance of microscopic observation drug susceptibility for the rapid diagnosis of tuberculosis and detection of drug resistance in Bamako, Mali. Clin Microbiol Infect 2017; 23:408.e1-408.e6. [PMID: 28110049 DOI: 10.1016/j.cmi.2017.01.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2016] [Revised: 11/08/2016] [Accepted: 01/04/2017] [Indexed: 01/01/2023]
Abstract
OBJECTIVES In Mali early detection and treatment of multidrug-resistant tuberculosis (MDR-TB) are still challenging due to the cost, time and/or complexity associated with regular tests. Microscopic Observation Drug Susceptibility (MODS) is a low-cost assay validated by WHO in 2010. It is a liquid-culture-based assay to detect the 'cording' characteristic of Mycobacterium tuberculosis complex and to assess susceptibility to both isoniazid and rifampicin defining multidrug-resistant tuberculosis (MDR-TB). In this study we aimed to evaluate the performance of MODS as diagnostic tool compared with a validated method-Mycobacteria Growth Indicator Tube/Antimicrobial Susceptibility Testing/Streptomycin, Isoniazid, Rifampicin and Ethambutol (MGIT/AST/SIRE). METHODS AND RESULTS Between January 2010 and October 2015 we included 98 patients with suspected TB in an observational cohort study. The sensitivity and specificity of MODS assay for detecting TB were respectively 94.12% and 85.71% compared with the reference MGIT/7H11 culture, with a Cohen κ coefficient of 0.78 (95% CI 0.517-1.043). The median time to culture positivity for MODS assay and MGIT (plus interquartile range, IQR) was respectively 8 days (IQR 5-11) and 6 days (IQR 5-6). In detecting patients with MDR-TB, the sensitivity and specificity of MODS assay were respectively 100% and 95.92%. The positive predictive value and negative predictive value were, respectively, 66.7% and 100%. The median turnaround times for obtaining MDR-TB results using MODS assay and MGIT/AST/SIRE was respectively 9 days and 35 days. Hence, the MODS assay rapidly identifies MDR-TB in Mali compared with the MGIT/AST/SIRE. CONCLUSION As an easy, simple, fast and affordable method, the MODS assay could significantly improve the management of TB.
Collapse
Affiliation(s)
- M Sanogo
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - B Kone
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - B Diarra
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali; Institute of Tropical Medicine (ITM), Biomedical Department, Antwerp, Belgium.
| | - M Maiga
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali; Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., NCI Campus at Frederick, Frederick, MD, USA
| | - B Baya
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - A M Somboro
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - Y S Sarro
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - A C G Togo
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - B P P Dembele
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - D Goita
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - A Kone
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - O M'Baye
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - N Coulibaly
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - S Diabate
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - B Traore
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - M H Diallo
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - Y I Coulibaly
- Filariasis Unit of the Malaria Research and Training Centre (MRTC), USTTB, Bamako, Mali
| | - P Saleeb
- University of Maryland School of Medicine, Baltimore, MD, USA
| | - M Belson
- Division of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
| | - S Orsega
- Division of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
| | - S Siddiqui
- Division of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
| | - M A Polis
- Division of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
| | - S Dao
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - R L Murphy
- Division of Infectious Diseases, Northwestern University, Chicago, IL, USA
| | - S Diallo
- SEREFO Laboratories of the University Clinical Research Centre, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| |
Collapse
|
15
|
Soumaré DDN, Outtara K, Kanouté T, Toloba Y, Baya B, Diallo S. Aspect épidémiologiques et histopathologiques des cancers broncho-pulmonaires au Mali au cours d’une décennie : données du registre des cancers. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
16
|
Toloba Y, Kanouté T, Soumaré D, Ouattara K, Kamian Y, Baya B, M’Baye O, Berthé G, Diabaté S, Diallo S. Motif d’hospitalisation des cas de TPM+ en milieu hospitalier phtisiologique. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
17
|
Toloba Y, Cissé A, Soumaré D, Ouattara K, Kanouté T, Koné D, Diarra B, Baya B, Berthé G, Camara F, Konaté B, Diallo S. Apport du GeneXpert dans le diagnostic de la tuberculose et de la résistance à la rifampicine au Mali après 22 mois d’acquisition. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
18
|
Diarra B, Goita D, Tounkara S, Sanogo M, Baya B, Togo ACG, Maiga M, Sarro YS, Kone A, Kone B, M'Baye O, Coulibaly N, Kassambara H, Cisse A, Belson M, Polis MA, Otu J, Gehre F, Antonio M, Dao S, Siddiqui S, Murphy RL, de Jong BC, Diallo S. Tuberculosis drug resistance in Bamako, Mali, from 2006 to 2014. BMC Infect Dis 2016; 16:714. [PMID: 27894266 PMCID: PMC5126865 DOI: 10.1186/s12879-016-2060-7] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2016] [Accepted: 11/22/2016] [Indexed: 12/02/2022] Open
Abstract
Background Although Drug resistance tuberculosis is not a new phenomenon, Mali remains one of the “blank” countries without systematic data. Methods Between 2006 and 2014, we enrolled pulmonary TB patients from local TB diagnostics centers and a university referral hospital in several observational cohort studies. These consecutive patients had first line drug susceptibility testing (DST) performed on their isolates. A subset of MDR was subsequently tested for second line drug resistance. Results A total of 1186 mycobacterial cultures were performed on samples from 522 patients, including 1105 sputa and 81 blood samples, yielding one or more Mycobacterium tuberculosis complex (Mtbc) positive cultures for 343 patients. Phenotypic DST was performed on 337 (98.3%) unique Mtbc isolates, of which 127 (37.7%) were resistant to at least one drug, including 75 (22.3%) with multidrug resistance (MDR). The overall prevalence of MDR-TB was 3.4% among new patients and 66.3% among retreatment patients. Second line DST was available for 38 (50.7%) of MDR patients and seven (18.4%) had resistance to either fluoroquinolones or second-line injectable drugs. Conclusion The drug resistance levels, including MDR, found in this study are relatively high, likely related to the selected referral population. While worrisome, the numbers remained stable over the study period. These findings prompt a nationwide drug resistance survey, as well as continuous surveillance of all retreatment patients, which will provide more accurate results on countrywide drug resistance rates and ensure that MDR patients access appropriate second line treatment. Electronic supplementary material The online version of this article (doi:10.1186/s12879-016-2060-7) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- B Diarra
- SEREFO Program, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali. .,Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
| | - D Goita
- SEREFO Program, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - S Tounkara
- SEREFO Program, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - M Sanogo
- SEREFO Program, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - B Baya
- SEREFO Program, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - A C G Togo
- SEREFO Program, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - M Maiga
- SEREFO Program, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - Y S Sarro
- SEREFO Program, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - A Kone
- SEREFO Program, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - B Kone
- SEREFO Program, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - O M'Baye
- SEREFO Program, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - N Coulibaly
- SEREFO Program, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - H Kassambara
- SEREFO Program, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - A Cisse
- Laboratoire National de Référence des Mycobactéries (LNR), Institut National de Recherche en Santé publique (INRSP), Bamako, Mali
| | - M Belson
- CCRB, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
| | - M A Polis
- CCRB, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
| | - J Otu
- Vaccines and Immunity Theme, Atlantic Boulevard, Medical Research Council (MRC), Fajara, Banjul, The Gambia
| | - F Gehre
- Vaccines and Immunity Theme, Atlantic Boulevard, Medical Research Council (MRC), Fajara, Banjul, The Gambia.,Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
| | - M Antonio
- Vaccines and Immunity Theme, Atlantic Boulevard, Medical Research Council (MRC), Fajara, Banjul, The Gambia.,Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.,Microbiology and Infection Unit, Warwick Medical School, University of Warwick, Coventry, UK
| | - S Dao
- SEREFO Program, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| | - S Siddiqui
- CCRB, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
| | - R L Murphy
- Global Health, Northwestern University, Chicago, IL, USA
| | - B C de Jong
- Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
| | - S Diallo
- SEREFO Program, University of Sciences, Techniques and Technologies of Bamako (USTTB), Bamako, Mali
| |
Collapse
|
19
|
Diallo S, Sissoko BF, Baya B, Toloba Y, Cayon I, M'baye O. [The socio-economic impact of asthmatic disease at Bamako about 131 cases]. Mali Med 2009; 24:57-60. [PMID: 20093206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
With an aim of evaluating the socio-economic impact of the asthmatic disease in Mali, a cross-sectional study was carried out of July 1st to September 30, 2006 in the district of Bamako. The study proceeded with the service of Pneumo-phthisiology of the CHU of the point G and in 4 of the 6 drawn health center of reference of the district to the fate. 131 asthmatic patients were indexed on 1595 consultations is a frequency of 8, 24%. The average age was 31 years, the sex-ratio was of 1,2 in favour of the men. August recorded the greatest number of consultation is 50.4%. The antecedent of family asthma was found in 46, 6% of the cases, the nicotinism in 13% of the cases. The average therapeutic cost per annum rose of 75.750 is 115, 47 EUROS without hospitalization with 222.750 FCFA (339, 57 EUROS) FCFA with hospitalization. The hospital expenses rose on average to. 147000 FCFA (224, 09 EUROS) that is to say 66, 21% of the costs of assumption of responsibility. The intermediate duration of hospitalization was 5,5 days 1 to 4 days without activity was noted at 50.4% of the cases, on average 312 days of absence. The professional damage was announced in 13, 7%. The economic burden was supported by the father in 29% of the cases. In 42% of the cases in charge one of expenditure was civil servant. Asthma is a social disease from its impact on the family economy.
Collapse
Affiliation(s)
- S Diallo
- Service de Pneumo-phtisiologie CHU du Point G BP 333 Bamako, Mali
| | | | | | | | | | | |
Collapse
|
20
|
Baya B. [High infant mortality rates that can be substantially lowered]. Pop Sahel 1989:6-9. [PMID: 12316049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/19/2023]
|